Catch up on the latest updates on non-small cell lung cancer treatment from the 2024 American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, and the European Society for Medical Oncology Congress in this exclusive conference coverage series.
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
